StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/309% above fair value
$5.94−0.08 (-1.33%)

Close on Nov 18, 2026Market cap $1.30BP/E –Yield –

Ocular Therapeutix free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Ocular Therapeutix's free cash flow for the twelve months ending Jun 30, 2026 was -$255.10M. For fiscal 2025 it was -$216.89M. The highest annual figure on record is -$12.79M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$216.89M–
FY2024Dec 31, 2024-$135.97M–
FY2023Dec 31, 2023-$76.32M–
FY2022Dec 31, 2022-$63.32M–
FY2021Dec 31, 2021-$66.74M–
FY2020Dec 31, 2020-$54.40M–
FY2019Dec 31, 2019-$79.82M–
FY2018Dec 31, 2018-$51.12M–
FY2017Dec 31, 2017-$58.73M–
FY2016Dec 31, 2016-$35.92M–
FY2015Dec 31, 2015-$35.52M–
FY2014Dec 31, 2014-$21.76M–
FY2013Dec 31, 2013-$13.03M–
FY2012Dec 31, 2012-$12.79M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$70.64M–
Q1 FY2026Mar 31, 2026-$70.66M–
Q4 FY2025Dec 31, 2025-$57.09M–
Q3 FY2025Sep 30, 2025-$56.72M–
Q2 FY2025Jun 30, 2025-$56.48M–
Q1 FY2025Mar 31, 2025-$46.60M–
Q4 FY2024Dec 31, 2024-$39.63M–
Q3 FY2024Sep 30, 2024-$36.65M–
Q2 FY2024Jun 30, 2024-$25.54M–
Q1 FY2024Mar 31, 2024-$34.14M–
Q4 FY2023Dec 31, 2023-$22.91M–
Q3 FY2023Sep 30, 2023-$7.99M–
Q2 FY2023Jun 30, 2023-$22.07M–
Q1 FY2023Mar 31, 2023-$23.35M–
Q4 FY2022Dec 31, 2022-$19.11M–
Q3 FY2022Sep 30, 2022-$13.96M–
Q2 FY2022Jun 30, 2022-$11.37M–
Q1 FY2022Mar 31, 2022-$18.88M–
Q4 FY2021Dec 31, 2021-$15.78M–
Q3 FY2021Sep 30, 2021-$13.26M–
Q2 FY2021Jun 30, 2021-$20.19M–
Q1 FY2021Mar 31, 2021-$17.52M–
Q4 FY2020Dec 31, 2020-$6.50M–
Q3 FY2020Sep 30, 2020-$13.87M–
Q2 FY2020Jun 30, 2020-$14.92M–
Q1 FY2020Mar 31, 2020-$19.10M–
Q4 FY2019Dec 31, 2019-$20.07M–
Q3 FY2019Sep 30, 2019-$19.96M–
Q2 FY2019Jun 30, 2019-$19.67M–
Q1 FY2019Mar 31, 2019-$20.11M–
Q4 FY2018Dec 31, 2018-$14.13M–
Q3 FY2018Sep 30, 2018-$11.35M–
Q2 FY2018Jun 30, 2018-$12.79M–
Q1 FY2018Mar 31, 2018-$12.85M–
Q4 FY2017Dec 31, 2017-$10.95M–
Q3 FY2017Sep 30, 2017-$16.42M–
Q2 FY2017Jun 30, 2017-$15.13M–
Q1 FY2017Mar 31, 2017-$16.23M–
Q4 FY2016Dec 31, 2016-$8.29M–
Q3 FY2016Sep 30, 2016-$8.20M–

More Ocular Therapeutix figures

See a number that looks wrong?